Safety and Efficacy of Janus Kinase Inhibitors

EP: 1.Intro and Welcomes

EP: 2.Evolving Goals in Rheumatoid Arthritis Treatment: Defining and Achieving Clinical Remission

EP: 3.Prevalence and Management of Poorly Controlled Rheumatoid Arthritis in Clinical Practice

EP: 4.Complications and Prognostic Factors in Uncontrolled Rheumatoid Arthritis

EP: 5.Evaluating and Adjusting Rheumatoid Arthritis Treatment: Adhering to ACR Guidelines for csDMARDs and Advanced Therapies

EP: 6.Exploring the Discrepancy Between Patient Perception and Disease Activity Assessments

EP: 7.Achieving Low Disease Activity and Remission: Managing Patient Expectations

EP: 8.Guidance on Transitioning from TNFi to Non-TNF Targeted Therapies

EP: 9.Advanced Treatment Options for RA: Exploring the Data

EP: 10.Guiding Treatment Decisions: The Role of Remission Data and Head-to-Head Comparisons

EP: 11.JAK Inhibitors vs TNF Inhibitors: Effects on Administration, Efficacy, and Safety

EP: 12.JAK Inhibitor Selectivity and Dose-Related Toxicity

EP: 13.Outcomes of Class Switching vs Cycling TNF Inhibitors

EP: 14.Cycling Within TNF Inhibitors: Complications and Factors Influencing Treatment Choices

Now Viewing

EP: 15.Safety and Efficacy of Janus Kinase Inhibitors

EP: 16.Closing Remarks

Video content above is prompted by the following:

Results from the 2021 ORAL Surveillance study showed the Janus kinase inhibitor (JAKi) tofacitinib was associated with a cardiovascular and cancer risk.

• Can you describe concerns and misperceptions that ensued from results of the ORAL Surveillance study? What were the limitations of the study?
• Can you please share how you weigh JAKi safety concerns with their efficacy outcomes?
• In your clinical observations, what role have JAKis played in helping patients with rheumatoid arthritis achieve remission?